Paredes, Daniel A PHD

Early onset Alzheimer's disease occurs in eighty percent of individuals with Down syndrome with few therapeutic options available. This study provides the opportunity to use the polyamine pathway as a potential drug target that could be a contributing factor in the development of neuropathology underlying dementia in Down syndrome.